Biofil Chemicals and Pharmaceuticals Limited (BIOFILCHEM.BO)
INR 42.72
(0.73%)
INR 42.72
(0.73%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 13.06 Million INR | -35.43% |
| 2022 | 12.64 Million INR | -14.73% |
| 2021 | 14.83 Million INR | -38.01% |
| 2020 | 23.98 Million INR | 18.43% |
| 2019 | 19.94 Million INR | 79.76% |
| 2018 | 11.24 Million INR | 8.56% |
| 2017 | 10.36 Million INR | -62.47% |
| 2016 | 27.58 Million INR | 96.9% |
| 2015 | 14 Million INR | 15.79% |
| 2014 | 11.95 Million INR | 16.32% |
| 2013 | 10.39 Million INR | -4.44% |
| 2012 | 10.71 Million INR | 141.3% |
| 2011 | 4.5 Million INR | -61.46% |
| 2010 | 11.7 Million INR | 78.55% |
| 2009 | 6.55 Million INR | 260.39% |
| 2008 | -2.74 Million INR | -49.24% |
| 2007 | -2.73 Million INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 3.08 Million INR | -9.57% |
| 2023 Q1 | 4.42 Million INR | 0.23% |
| 2023 Q3 | 2.2 Million INR | -18.23% |
| 2023 Q4 | -326 Thousand INR | -114.77% |
| 2023 FY | - INR | -35.43% |
| 2023 Q2 | 2.69 Million INR | -38.99% |
| 2022 Q2 | 1.78 Million INR | -54.71% |
| 2022 FY | - INR | -14.73% |
| 2022 Q4 | 4.41 Million INR | 75.72% |
| 2022 Q3 | 2.51 Million INR | 40.89% |
| 2022 Q1 | 3.93 Million INR | 131.18% |
| 2021 Q1 | 3.53 Million INR | -1.86% |
| 2021 FY | - INR | -38.01% |
| 2021 Q3 | 5.54 Million INR | 37.48% |
| 2021 Q2 | 4.03 Million INR | 14.03% |
| 2021 Q4 | 1.7 Million INR | -69.28% |
| 2020 Q4 | 3.6 Million INR | -43.06% |
| 2020 Q2 | 10.55 Million INR | 207.66% |
| 2020 Q3 | 6.32 Million INR | -40.07% |
| 2020 FY | - INR | 18.43% |
| 2020 Q1 | 3.43 Million INR | -38.34% |
| 2019 Q4 | 5.56 Million INR | 57.86% |
| 2019 FY | - INR | 79.76% |
| 2019 Q1 | 1.66 Million INR | -48.83% |
| 2019 Q2 | 9.18 Million INR | 452.98% |
| 2019 Q3 | 3.52 Million INR | -61.61% |
| 2018 Q4 | 3.24 Million INR | -20.11% |
| 2018 FY | - INR | 8.56% |
| 2018 Q1 | 1.77 Million INR | -43.57% |
| 2018 Q2 | 2.15 Million INR | 21.11% |
| 2018 Q3 | 4.06 Million INR | 88.89% |
| 2017 Q3 | 3.32 Million INR | 82.78% |
| 2017 Q1 | 2.06 Million INR | -87.57% |
| 2017 Q2 | 1.81 Million INR | -11.83% |
| 2017 FY | - INR | -62.47% |
| 2017 Q4 | 3.14 Million INR | -5.3% |
| 2016 Q3 | 5.94 Million INR | 57.88% |
| 2016 Q2 | 3.76 Million INR | 194.07% |
| 2016 Q1 | 1.28 Million INR | -84.47% |
| 2016 Q4 | 16.58 Million INR | 178.91% |
| 2016 FY | - INR | 96.9% |
| 2015 FY | - INR | 15.79% |
| 2015 Q3 | 2.21 Million INR | 14.41% |
| 2015 Q1 | 1.57 Million INR | -70.99% |
| 2015 Q2 | 1.93 Million INR | 22.61% |
| 2015 Q4 | 8.24 Million INR | 272.28% |
| 2014 Q2 | 2.43 Million INR | 69.48% |
| 2014 Q4 | 5.44 Million INR | 167.74% |
| 2014 FY | - INR | 16.32% |
| 2014 Q3 | 2.03 Million INR | -16.41% |
| 2014 Q1 | 1.43 Million INR | -46.39% |
| 2013 Q3 | 4.99 Million INR | 321.98% |
| 2013 Q1 | 1.35 Million INR | -81.61% |
| 2013 FY | - INR | -4.44% |
| 2013 Q2 | 1.18 Million INR | -12.82% |
| 2013 Q4 | 2.67 Million INR | -46.38% |
| 2012 Q1 | 1.21 Million INR | -6.04% |
| 2012 Q4 | 7.37 Million INR | 589.06% |
| 2012 FY | - INR | 141.3% |
| 2012 Q3 | 1.07 Million INR | 1.9% |
| 2012 Q2 | 1.05 Million INR | -13.64% |
| 2011 FY | - INR | -61.46% |
| 2011 Q4 | 1.29 Million INR | 53.65% |
| 2011 Q3 | 843 Thousand INR | 0.0% |
| 2010 FY | - INR | 78.55% |
| 2009 FY | - INR | 260.39% |
| 2008 FY | - INR | -49.24% |
| 2008 Q4 | -3.03 Million INR | 0.0% |
| 2007 FY | - INR | 0.0% |
| 2007 Q4 | -3.03 Million INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 9.61 Billion INR | 99.864% |
| Aurobindo Pharma Limited | 61.78 Billion INR | 99.979% |
| Glenmark Life Sciences Limited | 6.86 Billion INR | 99.81% |
| Granules India Limited | 8.6 Billion INR | 99.848% |
| Indoco Remedies Limited | 2.64 Billion INR | 99.507% |
| Achyut Healthcare Limited | 524 Thousand INR | -2392.748% |
| Ajanta Pharma Limited | 12.56 Billion INR | 99.896% |
| Alkem Laboratories Limited | 24.19 Billion INR | 99.946% |
| Alpa Laboratories Limited | 86.12 Million INR | 84.834% |
| Brooks Laboratories Limited | 41.72 Million INR | 68.697% |
| AstraZeneca Pharma India Limited | 2.35 Billion INR | 99.446% |
| Bajaj HealthCare Limited | 444.51 Million INR | 97.062% |
| Bliss GVS Pharma Limited | 1.47 Billion INR | 99.117% |
| Dr. Reddy's Laboratories Limited | 88.27 Billion INR | 99.985% |
| Eris Lifesciences Limited | 6.98 Billion INR | 99.813% |
| FDC Limited | 4.4 Billion INR | 99.703% |
| Glenmark Pharmaceuticals Limited | 11.34 Billion INR | 99.885% |
| Gufic Biosciences Limited | 1.48 Billion INR | 99.118% |
| Ind-Swift Laboratories Limited | 6.86 Billion INR | 99.81% |
| Ipca Laboratories Limited | 13.29 Billion INR | 99.902% |
| Jagsonpal Pharmaceuticals Limited | 323.46 Million INR | 95.962% |
| Krebs Biochemicals & Industries Limited | -82.72 Million INR | 115.789% |
| Lasa Supergenerics Limited | -65.08 Million INR | 120.071% |
| Laurus Labs Limited | 8 Billion INR | 99.837% |
| Lupin Limited | 36.96 Billion INR | 99.965% |
| Mankind Pharma Limited | 28.09 Billion INR | 99.954% |
| Medicamen Biotech Limited | 245.66 Million INR | 94.683% |
| Medico Remedies Limited | 150.37 Million INR | 91.314% |
| Megasoft Limited | 284.73 Million INR | 95.413% |
| NATCO Pharma Limited | 18.79 Billion INR | 99.931% |
| Piramal Pharma Limited | 13.05 Billion INR | 99.9% |
| RPG Life Sciences Limited | 1.28 Billion INR | 98.981% |
| Sigachi Industries Limited | 883.39 Million INR | 98.521% |
| Sun Pharmaceutical Industries Limited | 138.36 Billion INR | 99.991% |
| Suven Pharmaceuticals Limited | 4.67 Billion INR | 99.721% |
| Syncom Formulations (India) Limited | 430.27 Million INR | 96.964% |
| Unichem Laboratories Limited | 742.35 Million INR | 98.24% |
| Wanbury Limited | 985.49 Million INR | 98.675% |
| Windlas Biotech Limited | 781.72 Million INR | 98.329% |
| ZIM Laboratories Limited | 462.09 Million INR | 97.173% |
| Zydus Lifesciences Limited | 56.22 Billion INR | 99.977% |
| Sun Pharma Advanced Research Company Limited | -3.73 Billion INR | 100.35% |
| Divi's Laboratories Limited | 25.43 Billion INR | 99.949% |
| Hester Biosciences Limited | 539.47 Million INR | 97.579% |
| Procter & Gamble Health Limited | 3.01 Billion INR | 99.567% |
| Amrutanjan Health Care Limited | 682.53 Million INR | 98.086% |
| Bal Pharma Limited | 345.59 Million INR | 96.22% |
| Strides Pharma Science Limited | 3.76 Billion INR | 99.653% |
| Venus Remedies Limited | 711.8 Million INR | 98.165% |
| Aarti Pharmalabs Limited | 3.9 Billion INR | 99.666% |
| Nectar Lifesciences Limited | 1.56 Billion INR | 99.165% |
| Shilpa Medicare Limited | 2.58 Billion INR | 99.495% |
| Aarti Drugs Limited | 3.24 Billion INR | 99.598% |
| IOL Chemicals and Pharmaceuticals Limited | 2.6 Billion INR | 99.499% |
| Suven Life Sciences Limited | -992.78 Million INR | 101.316% |
| Ind-Swift Limited | 1.06 Billion INR | 98.774% |
| Valiant Laboratories Limited | 12.73 Million INR | -2.536% |
| J. B. Chemicals & Pharmaceuticals Limited | 9.33 Billion INR | 99.86% |
| Solara Active Pharma Sciences Limited | -2.82 Billion INR | 100.463% |
| Themis Medicare Limited | 562.6 Million INR | 97.678% |
| Hikal Limited | 2.69 Billion INR | 99.515% |
| Torrent Pharmaceuticals Limited | 35 Billion INR | 99.963% |
| Sequent Scientific Limited | 549.8 Million INR | 97.624% |
| Novartis India Limited | 1.26 Billion INR | 98.971% |
| Wockhardt Limited | 1.08 Billion INR | 98.791% |
| Jubilant Pharmova Limited | 8 Billion INR | 99.837% |
| Neuland Laboratories Limited | 4.74 Billion INR | 99.725% |
| Morepen Laboratories Limited | 1.72 Billion INR | 99.243% |
| Kilitch Drugs (India) Limited | 287.42 Million INR | 95.456% |
| Mangalam Drugs & Organics Limited | 174.94 Million INR | 92.534% |